Genentech granted FDA orphan status for gastric cancer treatment

Roche's Genentech unit was granted FDA orphan designation for Ipatasertib for the treatment of gastric cancer including cancer of the gastro-esophageal junction, according to a post to the FDA website.

Advertisement